FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792978040> ?p ?o ?g. }

• W2792978040 endingPage "916" @default.
• W2792978040 startingPage "909" @default.
• W2792978040 abstract "The goal of this study was to assess the antitumor efficacy and safety of lobaplatin-based regimens as the second line of treatment in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes, compared with that of cisplatin-based regimens. During August 2012 to April 2015, 87 patients who received lobaplatin-based regimens or cisplatin-based regimens were included. Medical records of the patients noted that lobaplatin (30 mg/m2) or cisplatin (25 mg/m2), combined with another chemotherapeutic agent such as Gemcitabine (1000 mg/m2) or Vinorelbine (25 mg/m2), was intravenously given to the patients on a basis of twenty-one days as one treatment cycle. All the patients were followed until August 2017. The endpoint of this study was progression-free survival (PFS), overall survival (OS), and estimated objective response rate (RR). Safety and drug tolerability data were also obtained. Lobaplatin-based regimens prolonged PFS compared to cisplatin-based regimens (median 13.2 vs 4.7 months, hazard ratio = 0.37, 95% confidence intervals: 0.21–0.67, P = .0007), while OS was not significantly different between the two groups (hazard ratio = 0.72, 95% confidence intervals: 0.40–1.30, P = .2767), as was objective RR (37.8% vs 33.4%, x2 = 0.19, P = .6653). Nausea/vomiting and renal injury were more frequent with cisplatin-based regimens. Our results show that lobaplatin-based regimens are superior to cisplatin in terms of efficacy and are better tolerated." @default.
• W2792978040 created "2018-03-29" @default.
• W2792978040 creator A5019793698 @default.
• W2792978040 creator A5030429211 @default.
• W2792978040 creator A5039203018 @default.
• W2792978040 creator A5053699823 @default.
• W2792978040 creator A5065935918 @default.
• W2792978040 creator A5069456938 @default.
• W2792978040 creator A5084854649 @default.
• W2792978040 date "2018-07-01" @default.
• W2792978040 modified "2023-10-17" @default.
• W2792978040 title "Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment" @default.
• W2792978040 cites W1612286138 @default.
• W2792978040 cites W1801537031 @default.
• W2792978040 cites W1852032 @default.
• W2792978040 cites W186092189 @default.
• W2792978040 cites W1871271676 @default.
• W2792978040 cites W1908696053 @default.
• W2792978040 cites W1915584582 @default.
• W2792978040 cites W1972888300 @default.
• W2792978040 cites W1974370626 @default.
• W2792978040 cites W1991199427 @default.
• W2792978040 cites W1992507370 @default.
• W2792978040 cites W1993779806 @default.
• W2792978040 cites W2003175719 @default.
• W2792978040 cites W2009715180 @default.
• W2792978040 cites W2014750426 @default.
• W2792978040 cites W2033274910 @default.
• W2792978040 cites W2036879273 @default.
• W2792978040 cites W2037314771 @default.
• W2792978040 cites W2059393966 @default.
• W2792978040 cites W2074744795 @default.
• W2792978040 cites W2078067596 @default.
• W2792978040 cites W2085044126 @default.
• W2792978040 cites W2097313513 @default.
• W2792978040 cites W2100633600 @default.
• W2792978040 cites W2101539565 @default.
• W2792978040 cites W2107720790 @default.
• W2792978040 cites W2119609398 @default.
• W2792978040 cites W2128067825 @default.
• W2792978040 cites W2128587082 @default.
• W2792978040 cites W2136983579 @default.
• W2792978040 cites W2139296795 @default.
• W2792978040 cites W2148415679 @default.
• W2792978040 cites W2154658129 @default.
• W2792978040 cites W2156513436 @default.
• W2792978040 cites W2158129566 @default.
• W2792978040 cites W2158628995 @default.
• W2792978040 cites W2159777151 @default.
• W2792978040 cites W2170866964 @default.
• W2792978040 cites W2315980953 @default.
• W2792978040 cites W2321986134 @default.
• W2792978040 cites W2324030469 @default.
• W2792978040 cites W2335805918 @default.
• W2792978040 cites W2397614724 @default.
• W2792978040 cites W2403048455 @default.
• W2792978040 cites W2472960384 @default.
• W2792978040 cites W2560978526 @default.
• W2792978040 cites W2570618306 @default.
• W2792978040 cites W2589052327 @default.
• W2792978040 cites W2620646026 @default.
• W2792978040 cites W2739233478 @default.
• W2792978040 cites W2754505985 @default.
• W2792978040 cites W2755778068 @default.
• W2792978040 cites W2758763059 @default.
• W2792978040 cites W2762285338 @default.
• W2792978040 cites W2767614862 @default.
• W2792978040 cites W2768583786 @default.
• W2792978040 cites W3150412736 @default.
• W2792978040 cites W746256588 @default.
• W2792978040 doi "https://doi.org/10.1016/j.sjbs.2018.01.011" @default.
• W2792978040 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6087814" @default.
• W2792978040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30108440" @default.
• W2792978040 hasPublicationYear "2018" @default.
• W2792978040 type Work @default.
• W2792978040 sameAs 2792978040 @default.
• W2792978040 citedByCount "12" @default.
• W2792978040 countsByYear W27929780402018 @default.
• W2792978040 countsByYear W27929780402019 @default.
• W2792978040 countsByYear W27929780402020 @default.
• W2792978040 countsByYear W27929780402021 @default.
• W2792978040 countsByYear W27929780402022 @default.
• W2792978040 countsByYear W27929780402023 @default.
• W2792978040 crossrefType "journal-article" @default.
• W2792978040 hasAuthorship W2792978040A5019793698 @default.
• W2792978040 hasAuthorship W2792978040A5030429211 @default.
• W2792978040 hasAuthorship W2792978040A5039203018 @default.
• W2792978040 hasAuthorship W2792978040A5053699823 @default.
• W2792978040 hasAuthorship W2792978040A5065935918 @default.
• W2792978040 hasAuthorship W2792978040A5069456938 @default.
• W2792978040 hasAuthorship W2792978040A5084854649 @default.
• W2792978040 hasBestOaLocation W27929780401 @default.
• W2792978040 hasConcept C126322002 @default.
• W2792978040 hasConcept C143998085 @default.
• W2792978040 hasConcept C197934379 @default.
• W2792978040 hasConcept C207103383 @default.
• W2792978040 hasConcept C2776694085 @default.
• W2792978040 hasConcept C2778239845 @default.

• next